Available Technologies

ADDITIONAL FILTERS

Therapeutics

50 available technologies

Novel Esters and Amides Derived from Indolealkanol and Indolealkylamines as Selective Cyclooxygenase-2 (Cox-2) Inhibitors

A compound of the formula ##STR1## where: n, and X are as defined in the specification, and the compound possesses selectivity for inhibition of cyclooxygenase-2.

Carboxylic Acid Amides as Selective COX-2 Inhibitors

A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.

Selective Reversible Cyclooxygenase-2 Inhibitors

A method of altering specificity of cyclooxygenase-inhibiting compounds that have a COOH moiety by changing the various COOH containing compounds, such as indomethacin, into ester derivatives or into secondary amide derivatives.

ARF and ARF Mimics to Inhibit Myc Protein Function

The c-Myc oncogene is bound by p19Arf, which inhibits c-Myc's ability to transform cells while augmenting apoptosis. This provides the basis for screening assays that examine the ability of various candidate substances to promote p19Arf interactions, or to substitute therefor.

Indoleacetic Acid and Indenacetic Acid Derivatives as Therapeutic Agents with Reduced Gastrointestinal Toxicity

The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and gamma-secretase. Also provided are methods of using the derivatives to treat pathological disorders.

Targeting Notch 3 Receptor Function Using Specific Peptides and Antipeptide Biomolecules

Novel Diabetes Treatment

Treating Glioblastoma by a Combination Therapy of Gamma-secretase inhibitors and Farnesyltransferase Inhibitors

Scientists at Vanderbilt have developed a novel therapy for gliobastoma multiform that results in minimal recurrence of the tumor. The therapy combines two inhibitors that effectively compromise tumor cell growth and survival. The therapy can be followed by radiation, a common treatment for cancer cells.

Generation of Neuroprogenitor Cells and Neurons from Human Induced Pluripotent Stem Cells by the Dorsomorphin Analog DMH1

This technology describes a novel methodology wherein human-induced pluripotent stem cells can be differentiated into neural precuror cells using DMH1 (a dorsomorphin analog). Neural progenitor cells can then be further differentiated into tyrosine hydroxylase expressing neurons.

Anti-Blood vessel/epicardial substance monoclonal and polyclonal antibody

Inhibitors of Inward-rectifying potassium channels (insecticide)

Featured Video

2012 Highlights

A motion graphic video describing operational improvements and successes of FY2012. Click here for a full PDF report.